{"id":"NCT00553280","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy","officialTitle":"An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For Pain Associated With Diabetic Peripheral Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2007-11-05","resultsPosted":"2011-01-05","lastUpdate":"2021-01-25"},"enrollment":123,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Neuropathy, Painful"],"interventions":[{"type":"DRUG","name":"pregabalin","otherNames":[]}],"arms":[{"label":"pregabalin","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and efficacy of the long-term use of pregabalin at doses up to 600 mg/day in patients with painful diabetic peripheral neuropathy who have completed 13 weeks of dosing in Study A0081163","primaryOutcome":{"measure":"Summary of Adverse Events","timeFrame":"53 weeks","effectByArm":[{"arm":"Pregabalin","deltaMin":114,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":27,"countries":["Japan"]},"refs":{"pmids":["24843530"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081164&StudyName=A%20Long-Term%20Study%20To%20Evaluate%20Safety%20And%20Efficacy%20Of%20Pregabalin%20For%20Pain%20Associated%20With%20Diabetic%20Peripheral%20Neuropathy"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":123},"commonTop":["Nasopharyngitis","Weight increased","Somnolence","Dizziness","Oedema peripheral"]}}